Maltogenic alpha-amylase variants
CA 2321595 C · Owner: Novozymes A/S · Inventors: Frandsen, Torben Peter; Andersen, Carsten; Svendsen, Allan
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The inventors have modified the amino acid sequence of a maltogenic alphaamylase to obtain variants with improved properties based on the three-, dimensional structure of the maltogenic alpha-amylase Novamyl. The variants have altered physicochemical properties. e.g. an altered pH optimum improved , thermostability, increased specific activity an altered cleavage pattern or , an increased ability to reduce retrogradation of starch or staling of bread.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed February 26, 1999 and granted February 14, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended February 26, 2019.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by February 26, 2021.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.